Investigational drug · Phase 2
Trevogrumab
Also called: REGN1033, GDF8
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Obesity.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
1
Any phase or sponsor naming "Trevogrumab"
First trial start
2024
Mar 13, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Trevogrumab", any sponsor or status.
Conditions studied
As listed on its trial records.
- Obesity
Approved drugs for the same conditions: Obesity and weight management · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "Trevogrumab" as an intervention, largest first.
- A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass PreservationPivotal-lookingCompleted
Regeneron PharmaceuticalsRegeneron (REGN)
NCT06299098 · 1,005 participants · Start Mar 13, 2024 · Primary completion Jun 16, 2026
Drug: Trevogrumab-Part A; Trevogrumab-Part B and Part C and 5 more · For: Obesity
Sites: Anniston, Alabama; Cullman, Alabama; Phoenix, Arizona · 60 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Trevogrumab (anti-GDF8) with or without garetosmab (anti-activin A) for prevention of muscle loss during semaglutide-induced weight reduction in people with obesity (COURAGE): a two-part, phase 2, double-blind, placebo-controlled, randomised trial.
Mosenzon O, Rosenstock J, Raya JG, et al. · Lancet 2026
- Cerebrospinal Fluid Neuromarker Levels in Patients With Schizophrenia and Healthy Control Participants: A Proximity Extension Assay Study.
Hidese S, Hattori K, Enokida T, et al. · Biol Psychiatry Glob Open Sci 2026
- Musculoskeletal (Mal)adaptations in Response to a >ߙ30ߙ000-km Running Challenge.
Venckunas T, Chaillou T, Cesanelli L, et al. · J Cachexia Sarcopenia Muscle 2026
- The crystal structure of the activin B:Fst288 complex and computational insights into the broad antagonistic activity and specificity of follistatin.
Hok L, Walker RG, Howard JA, et al. · J Biol Chem 2026
- Retraction: GDF8 promotes the cell invasiveness in human trophoblasts by upregulating the expression of follistatin-like 3 through the ALK5-SMAD2/3 signaling pathway.
· Front Cell Dev Biol 2026
- Age-Dependent Effect of Myostatin Blockade in the mdx Mouse Model of Duchenne Muscular Dystrophy (DMD).
Bogdanovich S, Pistilli EE, Khurana TS · Muscles 2026
Also in development for Obesity
- CagrilintidePhase 320 trials
Novo Nordisk · Obesity, Overweight, Type 2 Diabetes
- BerobenatidePF-08653944, MET097Phase 319 trials
Pfizer · Obesity, Overweight and/or Obesity, Overweight
- RetatrutideLY3437943Phase 316 trials
Eli Lilly · Obesity, Overweight, Type 2 Diabetes
- Maridebart cafraglutideAMG 133Phase 314 trials
Amgen · Obesity, Overweight, Obstructive Sleep Apnea
- EloralintideLY3841136Phase 313 trials
Eli Lilly · Obesity, Overweight, Diabetes Mellitus, Type 2
- HRS9531Phase 313 trials
Fujian Shengdi Pharmaceutical Co., Ltd. · Type 2 Diabetes, Chronic Management of Body Weight, Metabolic Dysfunction-Associated Steatohepatitis (MASH)
- NNC0487-0111Phase 312 trials
Novo Nordisk · Obesity, Overweight, Obstructive Sleep Apnoea
- HRS-7535Phase 310 trials
Shandong Suncadia Medicine Co., Ltd. · Type 2 Diabetes, Chronic Kidney Disease, Adults With Heart Failure, Mild Decrease in Ejection Fraction/Preserved Ejection Fraction, and Obesity
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Regeneron.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.